Gevorg Tamamyan, Co-Founder and Editor-in-Chief of OncoDaily, President of SIOP Asia Continental Branch, and Pediatric Oncology East and Mediterranean (POEM) Group, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Here we present the first results from the BPDCN International Registry, established by the Immune Oncology Research Institute.
BPDCN is a rare and aggressive hematologic malignancy. In this initial report, we captured data from 36 patients across 12 countries—a meaningful start for a disease where every case matters.
Since then, the registry has more than doubled in size. New centers and additional countries have joined this growing international effort. Yet for rare malignancies like BPDCN, more is not optional—it is essential. Progress depends on collecting the most comprehensive, global dataset possible.
If you are a hematologist–oncologist, pediatric or adult, anywhere in the world, and you have managed or are managing a BPDCN case, we invite you to join this collaboration.
For rare diseases, collaboration is not an advantage. It is the only way forward.”
Title: Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program
Authors: Astghik Voskanyan, Maria Badikyan, Marina Konopleva, Alvaro Alencar, Arusyak Ivanyan, Carolyn Owen, Consolato M. Sergi, Ching-Tien Peng, Dickran Kazandjian, Justin Taylor, Funda Tekkesin, Hasanein Ghali, Karen Bedirian, Maria Paola Martelli, Enrico Attardi, Maria Teresa Voso, Mariam Abramashvili, Mazin Faisal Al-Jadiry, Michalis Michael, Min-Yu Su, Nare Martirosyan, Nerses Ghahramanyan, Nino Totogashvili, Pavel P. Kotoucek, Rejin Kebudi, Robin Ohannessian, Ruzanna Papyan, Shushan Hovsepyan, Salma Elashwah, Sameer Bakhshi, Samvel Bardakhchyan, Samvel Danelyan, Shaimaa El-Ashwah, Tezer Kutluk, Deniz Tuğcu, Ahmad Alhuraiji, Vassilios Lazaris, Gevorg Tamamyan, Naveen Pemmaraju
Read the Full Article on Discover Oncology
More posts featuring Gevorg Tamamyan.